Goldman Sachs’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $36.7M | Buy |
2,042,501
+964,249
| +89% | +$18.2M | ﹤0.01% | 2076 |
|
|
2026
Q1 | $23.5M | Buy |
1,078,252
+514,766
| +91% | +$9.96M | ﹤0.01% | 2286 |
|
|
2025
Q4 | $12.1M | Buy |
563,486
+386,335
| +218% | +$8.14M | ﹤0.01% | 2904 |
|
|
2025
Q3 | $3.41M | Sell |
177,151
-199,133
| -53% | -$3.55M | ﹤0.01% | 4006 |
|
|
2025
Q2 | $6.43M | Buy |
376,284
+194,209
| +107% | +$8.29M | ﹤0.01% | 3174 |
|
|
2025
Q1 | $11.6M | Sell |
182,075
-294,991
| -62% | -$31.1M | ﹤0.01% | 2558 |
|
|
2024
Q4 | $58M | Buy |
477,066
+176,045
| +58% | +$21.6M | 0.01% | 1172 |
|
|
2024
Q3 | $37.6M | Sell |
301,021
-138,556
| -32% | -$19.2M | 0.01% | 1485 |
|
|
2024
Q2 | $69.5M | Buy |
439,577
+189,530
| +76% | +$24.3M | 0.01% | 965 |
|
|
2024
Q1 | $32.4M | Buy |
250,047
+65,177
| +35% | +$7.98M | 0.01% | 1471 |
|
|
2023
Q4 | $17.8M | Sell |
184,870
-558,022
| -75% | -$53.5M | ﹤0.01% | 2010 |
|
|
2023
Q3 | $90.1M | Sell |
742,892
-226,396
| -23% | -$25.6M | 0.02% | 771 |
|
|
2023
Q2 | $111M | Buy |
969,288
+211,216
| +28% | +$27.2M | 0.02% | 668 |
|
|
2023
Q1 | $104M | Sell |
758,072
-480,755
| -39% | -$62.4M | 0.02% | 682 |
|
|
2022
Q4 | $161M | Buy |
1,238,827
+102,134
| +9% | +$11.8M | 0.04% | 497 |
|
|
2022
Q3 | $126M | Sell |
1,136,693
-274,230
| -19% | -$27.6M | 0.03% | 574 |
|
|
2022
Q2 | $106M | Buy |
1,410,923
+486,867
| +53% | +$35.8M | 0.03% | 648 |
|
|
2022
Q1 | $72.2M | Sell |
924,056
-82,149
| -8% | -$6.29M | 0.02% | 991 |
|
|
2021
Q4 | $90.6M | Buy |
1,006,205
+133,210
| +15% | +$11.4M | 0.02% | 872 |
|
|
2021
Q3 | $80.7M | Sell |
872,995
-17,004
| -2% | -$1.31M | 0.02% | 887 |
|
|
2021
Q2 | $69.2M | Buy |
889,999
+175,587
| +25% | +$13.3M | 0.02% | 1005 |
|
|
2021
Q1 | $53.2M | Sell |
714,412
-335,605
| -32% | -$31M | 0.01% | 1129 |
|
|
2020
Q4 | $179M | Sell |
1,050,017
-204,564
| -16% | -$30.3M | 0.05% | 370 |
|
|
2020
Q3 | $176M | Buy |
1,254,581
+1,393
| +0.1% | +$212K | 0.05% | 371 |
|
|
2020
Q2 | $201M | Sell |
1,253,188
-72,684
| -5% | -$9.89M | 0.06% | 308 |
|
|
2020
Q1 | $130M | Buy |
1,325,872
+217,352
| +20% | +$24.8M | 0.05% | 412 |
|
|
2019
Q4 | $143M | Buy |
1,108,520
+81,222
| +8% | +$8.2M | 0.04% | 521 |
|
|
2019
Q3 | $77.4M | Buy |
1,027,298
+464,818
| +83% | +$54.9M | 0.02% | 814 |
|
|
2019
Q2 | $85.5M | Sell |
562,480
-110,793
| -16% | -$13.5M | 0.02% | 778 |
|
|
2019
Q1 | $80.2M | Buy |
673,273
+41,069
| +6% | +$5.28M | 0.02% | 803 |
|
|
2018
Q4 | $69M | Buy |
632,204
+94,960
| +18% | +$11.9M | 0.02% | 843 |
|
|
2018
Q3 | $86.8M | Sell |
537,244
-298,470
| -36% | -$40.8M | 0.02% | 853 |
|
|
2018
Q2 | $110M | Buy |
835,714
+152,785
| +22% | +$14.4M | 0.03% | 666 |
|
|
2018
Q1 | $50.6M | Sell |
682,929
-56,886
| -8% | -$3.79M | 0.01% | 1191 |
|
|
2017
Q4 | $41.2M | Buy |
739,815
+74,852
| +11% | +$3.97M | 0.01% | 1427 |
|
|
2017
Q3 | $30.2M | Sell |
664,963
-149,005
| -18% | -$5.96M | 0.01% | 1662 |
|
|
2017
Q2 | $27.4M | Buy |
813,968
+281,076
| +53% | +$9.15M | 0.01% | 1685 |
|
|
2017
Q1 | $15.8M | Buy |
532,892
+294,529
| +124% | +$9.12M | ﹤0.01% | 2059 |
|
|
2016
Q4 | $6.54M | Sell |
238,363
-44,620
| -16% | -$1.79M | ﹤0.01% | 2820 |
|
|
2016
Q3 | $17.4M | Sell |
282,983
-158,793
| -36% | -$4.8M | 0.01% | 2004 |
|
|
2016
Q2 | $8.42M | Buy |
441,776
+326,849
| +284% | +$6.05M | ﹤0.01% | 2445 |
|
|
2016
Q1 | $2.24M | Buy |
114,927
+100,042
| +672% | +$1.75M | ﹤0.01% | 3366 |
|
|
2015
Q4 | $575K | Sell |
14,885
-11,314
| -43% | -$367K | ﹤0.01% | 4803 |
|
|
2015
Q3 | $841K | Sell |
26,199
-80,609
| -75% | -$2.74M | ﹤0.01% | 4646 |
|
|
2015
Q2 | $3.25M | Buy |
106,808
+47,547
| +80% | +$972K | ﹤0.01% | 3357 |
|
|
2015
Q1 | $787K | Sell |
59,261
-27,720
| -32% | -$369K | ﹤0.01% | 4692 |
|
|
2014
Q4 | $1.26M | Buy |
86,981
+63,757
| +275% | +$1.08M | ﹤0.01% | 4324 |
|
|
2014
Q3 | $490K | Sell |
23,224
-15,652
| -40% | -$353K | ﹤0.01% | 5289 |
|
|
2014
Q2 | $1.16M | Buy |
38,876
+16,708
| +75% | +$528K | ﹤0.01% | 4559 |
|
|
2014
Q1 | $533K | Buy |
22,168
+15,320
| +224% | +$391K | ﹤0.01% | 5231 |
|
|
2013
Q4 | $139K | Sell |
6,848
-2,087
| -23% | -$62K | ﹤0.01% | 6142 |
|
|
2013
Q3 | $422K | Sell |
8,935
-136,630
| -94% | -$5.26M | ﹤0.01% | 5284 |
|
|
2013
Q2 | $5.54M | Buy |
+145,565
| New | +$5.21M | ﹤0.01% | 2628 |
|
Other funds holding SRPT
EAM
Goldman Sachs's SRPT Position: Q2 2026 in Review
Goldman Sachs increased its Sarepta Therapeutics (SRPT) stake by 89% in Q2 2026, buying an estimated $18.2M and bringing the position to 2,042,501 shares worth $36.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2076.
Goldman Sachs first reported a position in SRPT in Q2 2013 and has held it in 53 quarters since. The position peaked at $201M in Q2 2020. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Goldman Sachs held 2,042,501 shares of Sarepta Therapeutics worth $36.7M as of Q2 2026.
- Goldman Sachs bought 964,249 Sarepta Therapeutics shares in Q2 2026, an estimated $18.2M.
- Sarepta Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2076 holding.
- Goldman Sachs first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 53 quarters since.
- Goldman Sachs's Sarepta Therapeutics position peaked at $201M in Q2 2020.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.